Viewing nowCombinationValsartan and Amlodipine Tablets 5/160 mg
Valsartan 160mg · Amlodipine Besylate 6.94mg
Tablet · Prescription medication · Combination
Kyungdong Pharm Co., Ltd.

MFDS item code 201308376 · Approved 2013.07.25 · Insurance code 648103280
Treatment of essential hypertension not controlled with monotherapy
This medication is used to stably manage the blood pressure of patients with essential hypertension whose blood pressure is not sufficiently controlled by monotherapy with amlodipine or valsartan.
The recommended dose is 1 tablet once daily, taken with water, regardless of meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or valsartan). However, if blood pressure is not controlled with monotherapy using an individual component, switching directly to this medicine may be considered as follows. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. Patients taking valsartan and amlodipine concomitantly may switch to this medicine (a fixed-dose combination containing the same amounts of each active ingredient) for convenience. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or greater); however, this medicine should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients receiving dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. This medicine should not be administered to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Elderly patients aged 65 years or older: Caution should be exercised when increasing the dose.
Use of this medicine is not recommended in pediatric patients under 18 years of age because its safety and efficacy have not been established.
This medication can cause serious harm to the fetus and newborn if taken during the second or third trimester of pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Do not use in patients with allergies to any of the main ingredients or similar substances, women who are pregnant or breastfeeding, or patients with severe kidney or liver disease. Patients with sodium or fluid depletion may experience hypotension, so their condition should be controlled prior to taking this medication, and they should be carefully monitored during use. Patients with high potassium levels or those who take medications that may increase potassium levels should have their potassium levels checked frequently. Caution is required for patients with impaired kidney function or those who have received a kidney transplant, and the medication should be discontinued immediately if symptoms of angioedema occur. Patients with heart failure or those recovering from myocardial infarction should have their kidney function changes closely monitored, and attention should be paid to the possibility of side effects such as pulmonary edema. This medication may cause dizziness or fatigue when driving or operating machinery, so caution is advised. When used with other medications, there may be potential interactions, so it is essential to consult with a doctor or pharmacist, especially with potassium supplements, diuretics, and NSAIDs. In the case of an overdose, severe hypotension, reflex tachycardia, or shock may occur, so contact a medical institution immediately for appropriate treatment. Safety and efficacy have not been established for pediatric patients under 18 years of age, and therefore use in this population is not recommended.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect from air and moisture. It is recommended to maintain a storage temperature between 1 degree and 30 degrees Celsius at room temperature.
Dark yellow oval film-coated tablet
28 tablets (7 tablets/Alu-Alu x 4), 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationValsartan 160mg · Amlodipine Besylate 6.94mg
Tablet · Prescription medication · Combination
Kyungdong Pharm Co., Ltd.
CombinationValsartan 160mg · Amlodipine Besylate 6.94mg
Tablet · Prescription medication · Combination
Novartis Korea Co., Ltd.
CombinationValsartan 80mg · Amlodipine Besylate 6.94mg
Tablet · Prescription medication · Combination
Korea Novartis Co., Ltd.
CombinationValsartan 160mg · Amlodipine Besylate 13.87mg
Tablet · Prescription medication · Combination
Novartis Korea Co., Ltd.
Valsartan · Amlodipine Besylate
Prescription medication · Combination
Korea Sandose Co., Ltd.
Valsartan · Amlodipine Besylate
Prescription medication · Combination
Korea Sandos Co., Ltd.
Valsartan · Amlodipine Besylate
Prescription medication · Combination
Korea Sandos Co., Ltd.
CombinationValsartan 160mg · Amlodipine Besylate 13.87mg
Tablet · Prescription medication · Combination
Myungmoon Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.